PTAB challenges

The raw data provides: IPR2025-01124 — IPR — filed 2025-06-19 — last modified 2025-12-23 — status: Discretionary Denial — petitioner: Aerin Medical Inc. — inventor: David Townley. The patent owner is Neurent Medical Ltd. (from the patent document itself and search results).

Proceedings overview:
There is 1 AIA trial proceeding on US patent 11998262. Its status is "Discretionary Denial," meaning institution was denied. This gives a defendant a strong defensive posture, as the patent claims have not been challenged on the merits in this IPR.

---

IPR2025-01124 — Aerin Medical Inc. v. Neurent Medical Ltd.

• Type: Inter Partes Review
• Filed: 2025-06-19
• Status: Discretionary Denial — the PTAB declined to institute the inter partes review, meaning the merits of the patentability challenge were not fully considered.
• Judge panel: The institution decision was made by the USPTO Director, in consultation with at least three PTAB judges, as per new bifurcated review procedures implemented in March 2025. The search results did not explicitly name the panel members for this specific case, but did mention Acting Director Coke Morgan Stewart and later Director John Squires as involved in discretionary denials around this time.
• Petition grounds: The petition challenged claims of U.S. Patent No. 11,998,262. While specific claims and statutory bases (e.g., § 102 / § 103) were not explicitly detailed in the search snippets, Neurent's preliminary response argued against the sufficiency of the petition's expert testimony regarding treatment outcomes and the identification of electrodes, and argued that the claimed treatment outcomes were not in the prior art. Aerin Medical Inc. challenged four Neurent patents, including this one, covering nasal treatment devices, on prior art grounds.
• Institution decision: Denied on 2025-11-05. The denial was discretionary. Neurent Medical Ltd. (Patent Owner) argued that Aerin Medical Inc. (Petitioner) waited nearly a year after assertion to file IPR petitions on newly issued patents, even though the statute only permits IPR filing nine months after issuance. Neurent argued that Aerin should have pursued Post-Grant Review (PGR) within nine months of issuance and by foregoing PGR and filing overlapping invalidity arguments in district court, Aerin demonstrated IPR would not serve as a true alternative forum. This denial was likely influenced by the USPTO's shifting approach to discretionary denials, including considerations like "settled expectations" and the presence of parallel district court litigation.
• Final Written Decision (if issued): Not issued due to discretionary denial.
• Settlement / termination: The proceeding was terminated by discretionary denial of institution, not settlement.
• Appeal: Not applicable, as institution was denied and institution decisions cannot be appealed.
• Defensive value: This proceeding is highly favorable for Neurent Medical Ltd. The claims of US11998262 were not evaluated on their merits, and the IPR was denied institution, strengthening the patent's posture against this specific petitioner on the grounds raised. A defendant would face a higher hurdle to challenge this patent via IPR if the circumstances for denial (e.g., timing, parallel litigation) are similar.

---

Strategic summary

One AIA trial proceeding has been filed against US patent 11998262, specifically IPR2025-01124. This proceeding resulted in a discretionary denial of institution, meaning the claims of the patent were not formally challenged on their merits by the PTAB. As a result, all claims of US11998262 remain UNTESTED in AIA trial proceedings. The patent has not been narrowed through this IPR.

The estoppel landscape for IPR2025-01124 means that Aerin Medical Inc. (and its privies) are barred from bringing any invalidity arguments they raised or reasonably could have raised in this IPR. For other potential defendants, this specific denial highlights the PTAB's recent inclination towards discretionary denials based on factors such as the timing of the petition relative to patent issuance, the availability of other review options like PGR, and the existence of parallel district court litigation. The patent owner, Neurent Medical Ltd., successfully argued for discretionary denial, which indicates a strong defensive strategy against IPR challenges.

A significant pattern signal is that this IPR was part of a series of petitions (IPR2025-01124 to -01127) filed by Aerin Medical Inc. against Neurent Medical's newly issued patents. The denial, issued around November 2025, reflects the USPTO Director's increased involvement in institution decisions and a trend of denying institution in a significant number of cases without detailed reasoning, particularly for newly issued patents where PGR might have been an option.

Recommended next steps

For a defendant facing assertion of US patent 11998262, it is crucial to understand the specific reasons for the discretionary denial in IPR2025-01124. This denial means the patent claims were not invalidated, and the patent owner successfully leveraged PTAB procedural rules. Any future IPR petitions would need to carefully consider the "Fintiv factors" and other discretionary denial criteria, such as "settled expectations," especially if there is parallel district court litigation or if the patent has been known for a significant period. Since the denial was discretionary, the claims of 11998262 have not been substantively confirmed as patentable by the PTAB, but a new challenger would need to present a compelling argument to overcome the prior discretionary denial.

The official PTAB documents for IPR2025-01124, including the Patent Owner's Preliminary Response and the institution decision, would provide the most detailed reasoning for the discretionary denial and are essential for formulating a future defensive strategy. These documents can typically be accessed via the USPTO PTAB E2E system.## Proceedings overview
There is one AIA trial proceeding on US patent 11998262, IPR2025-01124. This proceeding concluded with a discretionary denial of institution, meaning the PTAB did not reach the merits of the patentability challenge. This outcome strengthens the defensive posture for Neurent Medical Ltd., as the patent claims have not been invalidated.

IPR2025-01124 — Aerin Medical Inc. v. Neurent Medical Ltd.

• Type: Inter Partes Review
• Filed: 2025-06-19
• Status: Discretionary Denial — The Patent Trial and Appeal Board (PTAB) declined to institute the inter partes review, thus the merits of the patentability challenge were not fully adjudicated.
• Judge panel: The decision to deny institution was made by the USPTO Director, in consultation with at least three PTAB judges, reflecting a new bifurcated review process implemented in March 2025. While specific administrative patent judges were not named in the search results, Acting Director Coke Morgan Stewart and later Director John Squires were involved in such discretionary denials during this period.
• Petition grounds: Aerin Medical Inc. challenged claims of U.S. Patent No. 11,998,262 on prior art grounds. The Patent Owner's Preliminary Response (POPR) argued against the sufficiency of the Petitioner's expert testimony regarding treatment outcomes and the identification of electrodes, asserting that the claimed treatment outcomes were not disclosed in the cited prior art.
• Institution decision: Denied on 2025-11-05. The denial was discretionary, with Neurent Medical Ltd. arguing that Aerin Medical Inc. had waited nearly a year after assertion to file the IPR petition for this newly issued patent (issued in 2024), suggesting that Post-Grant Review (PGR) should have been pursued within the statutory nine-month window. Neurent further contended that by foregoing PGR and filing overlapping invalidity arguments in district court, Aerin demonstrated that IPR would not serve as a true alternative forum. This decision aligns with the USPTO's expanded application of discretionary denial factors, including "settled expectations" and the presence of parallel district court litigation.
• Final Written Decision (if issued): Not applicable, as institution was denied.
• Settlement / termination: The proceeding was terminated by the discretionary denial of institution, not by settlement.
• Appeal: Not applicable, as institution decisions are not appealable.
• Defensive value: This proceeding represents a significant defensive win for Neurent Medical Ltd. The patent claims were not subjected to a full validity challenge on the merits at the PTAB. For any party facing assertion of this patent, it indicates that future IPR challenges will need to carefully navigate the USPTO's discretionary denial framework, particularly concerning timing relative to patent issuance and any existing parallel litigation.

Strategic summary

All claims of US11998262 remain UNTESTED by the PTAB on their merits in AIA trial proceedings. IPR2025-01124 resulted in a discretionary denial of institution, which means no claims were invalidated or sustained by a Final Written Decision. This outcome is favorable for the patent owner, Neurent Medical Ltd., as it leaves the patent's claims intact without any adverse validity rulings from the PTAB.

The estoppel landscape indicates that Aerin Medical Inc., as the petitioner in IPR2025-01124, and its privies, are now barred from raising any unpatentability grounds that were raised or reasonably could have been raised in that petition. For other potential defendants, the grounds for the discretionary denial (e.g., alleged delay in filing, availability of PGR, and parallel litigation) highlight specific vulnerabilities to consider if contemplating a new IPR challenge against this patent.

A clear pattern signal is that IPR2025-01124 was part of a series of IPRs filed by Aerin Medical Inc. against Neurent Medical Ltd. for recently issued patents. The denial reflects the USPTO Director's policy shift towards personally handling institution decisions and a trend of denying petitions, especially for newer patents where Post-Grant Review could have been an option. This aggressive defensive posture by the patent owner, successfully arguing for discretionary denial, suggests that future IPR attempts may encounter similar resistance.

Recommended next steps

For a defendant currently being asserted against, the discretionary denial of IPR2025-01124 means that the patent claims have not been formally adjudicated as unpatentable. While this is a win for the patent owner, it does not confirm the patentability of the claims on the merits. A defendant should:

• Review the specific institution decision: Obtain and thoroughly review the full institution decision for IPR2025-01124 (Paper 10, filed 2025-11-05, as indicated by snippet) to understand the precise reasoning for the discretionary denial. This document will detail the arguments made by both Aerin Medical Inc. and Neurent Medical Ltd. regarding discretionary factors. This can be accessed via the USPTO PTAB E2E system.
• Assess potential IPR viability: If considering a new IPR, carefully analyze the "Fintiv factors" and other discretionary considerations, such as "settled expectations", that led to the denial in IPR2025-01124. Evaluate whether your specific circumstances (e.g., timing of challenge, absence of parallel litigation, presentation of novel prior art or arguments) would lead to a different outcome.
• Consider alternative validity challenges: Explore other avenues for challenging validity, such as ex parte reexamination or district court litigation, if the IPR route appears too risky due to the precedent set by IPR2025-01124.